Q1 2025 sales update
The Q1 2025 sales update have been published on April 16, 2025 at 7H00 and a conference call took place at 14H00 CET.
The latest highlights from Investor Relations
Find out what’s been happening at Ipsen Investor Relations lately – including financial results, announcements, IR events, and more.
– 16 April 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
– 10 April 2025
Q1 2025 sales update
– 13 March 2025
Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s
– 13 February 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and…
– 12 January 2025
J.P. Morgan Healthcare Conference
INVESTING FOR GROWTH
We see everyone within the Ipsen investor community as a valued stakeholder who helps drive our overall success. Dedicated to transparency and ethical decision-making, we aim to provide investors with the resources they need to understand our company and how we plan to reach our ambitious targets.
Underpinned by a robust balance sheet and strong cash generation, we have the ambition to replenish our pipeline. With a successful strategy, we’re proud to be backed by an investor community that recognizes our positive progress.
Ipsen in Brief
We are a global biopharmaceutical company with a focus on transformative medicines in our three therapeutic areas of Oncology, Rare Disease and Neuroscience.
Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.
Strong results backed by innovation
With total sales growth of over 9%*, we delivered strong results in 2024, and we’ve had a strong start to 2025. We are on track to build further momentum in our transformation, and to achieve our objectives for the year. *At constant exchange rate.
Download Ipsen’s Annual ReportInvestor events
Ipsen is dedicated to providing investors with the tools they need to understand our company and goals. Our events offer investors the opportunity to meet our management and investor-relations teams and learn more about our strategy.
– 02 September 2025
Roadshow UK
– 03 September 2025
BioVoyage – EU Biopharma Bus Tour 2025
– 03 September 2025
Back to School Healthcare Series (4:00 – 4:45 PM CET)
– 09 September 2025
21st Annual Global Healthcare Conference
– 12 September 2025
Forum by Market Solutions
– 23 September 2025
Global Healthcare Conference
– 18 November 2025
European HC Conference
– 12 December 2025
Strategic Decisions Conference (SDC)
Pipeline
Innovating for a healthy tomorrow
Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across our three therapeutic areas of Oncology, Rare Disease and Neuroscience.
Shareholder information
We aim to transparently communicate to our investor community our analyst coverage, ADR program and shareholding structure.
Learn more
Regulated information
Information on voting rights updates, combined shareholders’ meeting and our share buyback program. View the publications and press releases related to regulated information.
Learn moreFIVE-YEAR STOCK INFORMATION
Share price and stock information, benchmark, orders, transactions: discover the data related to Ipsen’s shares.
Your dedicated contacts
-
Khalid Deojee
Senior Manager, Investor Relations
